

## DORSET MEDICINES ADVISORY GROUP Recommendation Summary

Formerly the Bournemouth, Dorset and Poole Health Technologies Forum, DMAG represents the four provider Trusts and GPs within the Clinical Commissioning Group (CCG). It provides recommendations to the CCG on the prescribing and commissioning of medicines.

Summary of recommendations considered at a meeting of the group on 12<sup>th</sup> May 2015. Formulary entries and associated documents can be accessed at [www.dorsetformulary.nhs.uk](http://www.dorsetformulary.nhs.uk). The annual report for 2014/15 for DMAG is available at <http://www.dorsetccg.nhs.uk/aboutus/medicines-management/Dorset-Medicines-Advisory-Group.htm>

PRODUCT	DECISION	COMMENTS
<b>1. Products re-categorised</b>		
N/A		
<b>2. New requests</b>		
Pevanti® (Prednisolone )	Not recommended	The commissioning statement for Pevanti® (prednisolone) tablets advises a “not recommended” categorisation due to safety concerns.
Brimonidine	Amber	Shared cared guidelines approved.
<b>3. Products considered by NICE</b>		
Rivaroxaban in ACS	Amber	Commissioning statement and shared care guideline – agreed to support NICE TA 335

PRODUCT	DECISION	COMMENTS
Rifaximin	Amber	Commissioning statement and shared care guideline – agreed to support NICE TA 337
Empagliflozin	Green	Commissioning statement approved to support NICE TA 336
<b>4. Miscellaneous recommendations by DMAG</b>		
Aliskiren	Amber	Shared cared guidelines approved
Dronedarone	Amber	Shared cared guidelines approved
Ticagrelor	Amber	Shared cared guidelines approved

Classification of products:

'RED' drugs for hospital use only

'AMBER with shared care' drugs suitable for use with shared care arrangements

'AMBER' drugs suitable for use without shared care arrangements

'GREEN' drugs suitable for prescribing in primary and secondary care

'Not Recommended' – drugs not recommended for use in Dorset

The new traffic light system can be found on the Dorset CCG internet at: [Dorset CCG - Traffic light scheme](#)